Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) will release its first earnings report after the closing bell on Monday, Sept. 14.
Analysts expect the Kirkland, Washington-based company to report quarterly loss of 62 cents per share, versus a loss of 36 cents per share in the year-ago period. The consensus estimate for Kestra Medical Technologies’ quarterly revenue is $29.01 million. It reported $19.37 million last year, according to Benzinga Pro.
On Sept. 10, Kestra named Daniel Finney as Vice President of Research & Development.
Kestra Medical Technologies shares declined 2.1% to close at $23.57 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- BTIG analyst Marie Thibault maintained a Buy rating with a price target of $32 on Sept. 2, 2026. This analyst has an accuracy rate of 67%.
- JP Morgan analyst Robbie Marcus initiated coverage on the stock with an Overweight rating and a price target of $30 on Aug. 10, 2026. This analyst has an accuracy rate of 65%.
- Oppenheimer analyst Suraj Kalia initiated coverage on the stock with a Perform rating on July 21, 2026. This analyst has an accuracy rate of 58%.
- Goldman Sachs analyst David Roman maintained a Neutral rating and cut the price target from $22 to $17 on April 9, 2026. This analyst has an accuracy rate of 53%.
- Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and raised the price target from $27 to $28 on Dec. 12, 2025. This analyst has an accuracy rate of 66%.
Considering buying KMTS stock? Here’s what analysts think:
Photo via Shutterstock